Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
December 16, 2025 08:30 ET | Source: CytoDyn Inc.

December 2025 Letter to Shareholders

VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for...
December 08, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with...
December 01, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Resolution of Class Action Lawsuit

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
November 24, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Company to deliver a poster presentation on clinical data demonstrating sustained remissionfollowing immune checkpoint inhibitor therapy with or after leronlimab treatmentin patients with metastatic...